Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 10/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5862701 | 1.00 | TSHR (0.43) | TSHRALDH1A1LMNAHSD17B10MEN1 | |
| Methyl Alcohol SCHEMBL9146394 | 0.98 | FDPS (0.42) | TSHRALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL2454205 | 0.97 | FDPS (0.41) | TSHRALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL1929155 | 0.90 | — | — | |
| SCHEMBL9223093 | 0.89 | LMNA (0.39) | TSHRALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL1639544 | 0.84 | TSHR (0.50) | TSHRALDH1A1FDPSSMPD1GGPS1 | |
| SCHEMBL3346971 | 0.84 | TSHR (0.50) | TSHRALDH1A1FDPSSMPD1GGPS1 | |
| SCHEMBL7508589 | 0.83 | LMNA (0.62) | TSHRALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL1098322 | 0.83 | LMNA (0.48) | TSHRALDH1A1LMNAHSD17B10MEN1 | |
| SCHEMBL2166623 | 0.83 | LMNA (0.48) | TSHRALDH1A1LMNAHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110698402-B | Separation method of ouabain and 12-epi-ouabain | 川北医学院 | 2023-05-30 | — | — | CN | claimed |
| CN-110698402-A | Method for separating ouwu alkali and 12-epi-ouwu alkali | 川北医学院 | 2020-01-17 | — | — | CN | claimed |
| US-4978744-A | Synthesis of dolastatin 10 | ARIZONA BOARD OF REGENTS (US) | 1990-12-18 | — | — | US | claimed |
| CN-113166140-B | CDK8/19 inhibitors | 拜奥卡德联合股份公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023237795-A1 | USE OF THE (+)-ELATOL COMPOUND FOR TREATING OR PREVENTING A NAEGLERIA FOWLERI INFECTION | UNIVERSIDAD DE LA LAGUNA (ES) | 2023-12-14 | — | — | WO | disclosed |
| US-11840531-B2 | CDK8/19 inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2023-12-12 | — | — | US | disclosed |
| CN-110698402-B | Separation method of ouabain and 12-epi-ouabain | 川北医学院 | 2023-05-30 | — | — | CN | disclosed |
| CN-110698402-B | Separation method of ouabain and 12-epi-ouabain | 川北医学院 | 2023-05-30 | — | — | CN | disclosed |
| CN-114316102-A | Alkoxy magnesium carrier, polyethylene catalyst and preparation method thereof | 北京吉海川科技发展有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3878022-A1 | METHOD FOR FORMING AN ORGANIC ELEMENT OF AN ELECTRONIC DEVICE | Merck Patent GmbH (DE) | 2021-09-15 | — | — | EP | disclosed |
| US-20210246138-A1 | CDK8/19 INHIBITORS | JOINT STOCK COMPANY "BIOCAD" (RU) | 2021-08-12 | — | — | US | disclosed |
| US-4654343-A | USEFUL AS ANXIOLYTIC OR ANTIEPILEPTIC AGENTS AS WELL AS SEDATIVE-HYPNOTIC AND SKELETAL MUSCLE RELAXANT AGENTS | AMERICAN CYANAMID COMPANY (US) | 1987-03-31 | — | — | US | disclosed |
| EP-0077536-B1 | 2'-SUBSTITUTED-SPIRO(BENZOFURAN-2(3H),1'-CYCLOALKANES), A PROCESS FOR PREPARING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-07-16 | — | — | EP | disclosed |
| US-4594435-A | ANTIDEPRESSANTS; ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1986-06-10 | — | — | US | disclosed |
| US-4517311-A | 2'-Substituted-spiro[benzofuran-2(3H),1'-cycloalkanes] and their analgesic and anti-depressant compositions | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-05-14 | — | — | US | disclosed |
| US-4509855-A | Dual liquid and gas chromatograph system | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0063858-B1 | LEUKOTRIENE ANALOGUES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Lilly Industries Limited (GB) | 1985-03-20 | — | — | EP | disclosed |
| US-4470699-A | Micro-column plasma emission liquid chromatograph | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1984-09-11 | — | — | US | disclosed |
| EP-0063858-A1 | Leukotriene analogues, their preparation and use in pharmaceutical compositions | Lilly Industries Limited (GB) | 1982-11-03 | — | — | EP | disclosed |
| US-4226856-A | ANTITUMOR AGENTS | UNIVERSITY PATENTS, INC. (US) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840531-B2 | CDK8/19 inhibitors | CDK8, CDK9, CDK18 | TSHR 3967/4885ALDH1A1 3487/4885LMNA 1767/4885 |
| US-20210246138-A1 | CDK8/19 INHIBITORS | CDK8, CDK9, CDK18 | TSHR 3967/4885ALDH1A1 3487/4885LMNA 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.